<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014919</url>
  </required_header>
  <id_info>
    <org_study_id>13546A</org_study_id>
    <nct_id>NCT05014919</nct_id>
  </id_info>
  <brief_title>Vortioxetine to Prevent Return of Symptoms in Children With Depression</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills)&#xD;
      in preventing depression in children who improved when treated with vortioxetine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a 12-week open-label, flexible-dose treatment period with vortioxetine,&#xD;
      followed by a 26-week, randomized, double-blind, fixed-dose, placebo-controlled&#xD;
      relapse-prevention period. There will be a safety follow up 4 weeks after the end of the&#xD;
      26-week double-blind treatment period.&#xD;
&#xD;
      The study population will include 'de novo' patients as well as 'rollover' patients from&#xD;
      other paediatric vortioxetine studies 12709A (NCT02709655) and 12712A (NCT02871297), who, in&#xD;
      the investigator's opinion, could benefit from continued treatment with vortioxetine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">December 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>Baseline/Randomisation to week 26 in the double-blind treatment period</time_frame>
    <description>Relapse defined as either a total score ≥40 on the Children Depression Rating Scale Revised Version (CDRS-R) total score with a history of 2 weeks of clinical deterioration, or clinical deterioration as judged by the clinician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>Baseline/Randomisation to week 26 in the double-blind treatment period</time_frame>
    <description>Relapse defined as either a total score ≥40 on the Children Depression Rating Scale Revised Version (CDRS-R) total score with a history of 2 weeks of clinical deterioration, or clinical deterioration as judged by the clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 26 in the CDRS-R total score</measure>
    <time_frame>Baseline/Randomisation to week 26 in the double-blind treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 26 in the Clinical Global Impression - Severity of Illness (CGI-S) score</measure>
    <time_frame>Baseline/Randomisation to week 26 in the double-blind treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Global Improvement (CGI-I) score at Week 26</measure>
    <time_frame>Week 26 in the double-blind treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) - Patient rated</measure>
    <time_frame>Baseline/Randomisation to week 26 in the double-blind treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of vortioxetine</measure>
    <time_frame>Baseline/Randomisation to week 26 in the double-blind treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Vortioxetine -open label treatment period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine - 5, 10, 15, and 20 mg/day, film-coated tablets, orally once daily.&#xD;
Patients will receive a targeted dose of 10 mg/day vortioxetine, however the investigator has the possibility to adjust the dose in case of unsatisfactory response or in case of dose-limiting adverse events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine -double-blind relapse prevention period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine - 5, 10, 15, and 20 mg/day, encapsulated film-coated tables, orally once daily.&#xD;
In the double-blind period, the patients will continue on the same fixed dose as during the end of the open label period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo -double-blind relapse prevention period</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - encapsulated tablets, orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Vortioxetine -double-blind relapse prevention period</arm_group_label>
    <arm_group_label>Vortioxetine -open label treatment period</arm_group_label>
    <other_name>Brintellix</other_name>
    <other_name>Trintellix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo -double-blind relapse prevention period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        De novo patients&#xD;
&#xD;
          -  The patient has a primary diagnosis of MDD according to DSM-5™ although co-morbid&#xD;
             anxiety disorders will be permitted (except Post Traumatic Stress Disorder (PTSD) and&#xD;
             Obsessive Compulsive Disorder (OCD)).&#xD;
&#xD;
          -  The patient has a CDRS-R total score ≥45 at the Screening and Baseline Visits.&#xD;
&#xD;
          -  The patient has a Clinical Global Impression - Severity of Illness (CGI-S) ≥4 at the&#xD;
             Screening and Baseline Visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient receives ongoing current psychotherapy that is planned to be intensified.&#xD;
             Interpersonal psychotherapy (IPT) or cognitive behavioural therapy (CBT) are not&#xD;
             allowed.&#xD;
&#xD;
          -  The patient presents with, or has a history of, an Axis I (DSM-5TM) diagnosis of&#xD;
             Bipolar Disorder, PTSD, OCD, Autism, Pervasive Developmental Disorder (PDD), or&#xD;
             Schizophrenia or Schizoaffective Disorder.&#xD;
&#xD;
          -  The patient has a diagnosis of attention-deficit/hyperactivity disorder (ADHD) and is&#xD;
             not maintained on a stable dose of a methylphenidate or amphetamine for a minimum of 4&#xD;
             weeks prior to the study treatment.&#xD;
&#xD;
          -  The patient has attempted suicide or is at significant risk of suicide&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AIM Trials, LLC</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C</name>
      <address>
        <city>Culiacan De Rosales</city>
        <state>Sinaloa</state>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BIND Investigaciones S.C</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Poznan</city>
        <zip>60744</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicorehabilitation Research Center Phoenix</name>
      <address>
        <city>Rostov-On-Don</city>
        <state>Rostov State</state>
        <zip>344010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

